The economic model that has underpinned the development of drug products for decades is currently under siege. Faced on one side with mounting pressure from payers to address affordability issues, pharmaceutical companies are facing ever more stringent regulatory requirements alongside … Read More
Author Archives: Oksana Pidmogylna
AARDEX Group and OnDosis Launch Collaboration to Bring Innovation to Drug Dosing in Clinical Trials
Liège, Belgium and Gothenburg, Sweden – October 15, 2024: AARDEX Group, a leader in managing drug exposure in clinical trials, and precision medicine innovators, and OnDosis, a game changer in precision dosing of oral solid medicines through the novel Dosage … Read More
One size fails all? The weight of evidence for personalized dosing in oral GLP-1 therapies
The Rise of GLP-1 Therapies In recent years, the pharmaceutical industry has borne witness to the meteoric rise of glucagon-like peptide-1 receptor agonist (GLP-1) therapies. Having fast become established as a potentially life-changing treatment for Type 2 diabetes and obesity, emerging … Read More
The Importance of Dose Optimisation in Oncology Clinical Trials
Global Cancer Challenges and the Need for Effective Dose Optimisation Let us first recognise the enormity of the challenges we are facing, on a global scale, when it comes to cancer. It is estimated that there were 18.1 million new … Read More
AARDEX Group and Compliance Meds Technologies sign collaboration agreement
AARDEX Group, the global leader in medication adherence solutions, has today announced a collaboration agreement with Compliance Meds Technologies (CMT), a mobile-health technology solutions provider. AARDEX MEMS® Adherence Software with Compliance Meds Technologies CleverCap® In this cooperation, the partners will … Read More
Innovative Approaches to Enhance and Measure Medication Adherence in Chronic Disease Management
Medication adherence is a vital component in managing chronic diseases effectively. However, it remains a significant challenge, with non-adherence rates reaching up to 50% among patients. This lack of adherence results in poor health outcomes and increased burdens on healthcare … Read More
Is the data from randomised clinical trials (RCT) random to the point of pointless?
In a recent paper titled ‘The impacts of undetected nonadherence in phase II, III and post-marketing clinical trials: An overview’ the authors detailed the findings of a research project which aimed to provide an overview of the consequences of unrecognized … Read More